N-[4-(Benzyloxy)-3-methoxybenzyl)]adamantane-1-amine (DZH2), a dual CCR5 and CXCR4 inhibitor as a potential agent against triple negative breast cancer.

MLA

Rostom, Monica M., et al. “N-[4-(Benzyloxy)-3-Methoxybenzyl)]Adamantane-1-Amine (DZH2), a Dual CCR5 and CXCR4 Inhibitor as a Potential Agent against Triple Negative Breast Cancer.” Archiv Der Pharmazie, vol. 358, no. 1, Jan. 2025, p. e2400146. EBSCOhost, https://doi.org/10.1002/ardp.202400146.

APA

Rostom, M. M., El-Zohairy, M. A., Marzouk, M. A., Berger, M. R., Schols, D., Assal, R. A., Mandour, Y. M., Adwan, H., & Zlotos, D. P. (2025). N-[4-(Benzyloxy)-3-methoxybenzyl)]adamantane-1-amine (DZH2), a dual CCR5 and CXCR4 inhibitor as a potential agent against triple negative breast cancer. Archiv Der Pharmazie, 358(1), e2400146. https://doi.org/10.1002/ardp.202400146

Chicago

Rostom, Monica M, Mariam A El-Zohairy, Mohamed A Marzouk, Martin R Berger, Dominique Schols, Reem A Assal, Yasmine M Mandour, Hassan Adwan, and Darius P Zlotos. 2025. “N-[4-(Benzyloxy)-3-Methoxybenzyl)]Adamantane-1-Amine (DZH2), a Dual CCR5 and CXCR4 Inhibitor as a Potential Agent against Triple Negative Breast Cancer.” Archiv Der Pharmazie 358 (1): e2400146. doi:10.1002/ardp.202400146.